The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain

Autor:	A, Navarro-Navarro, D, Salom, J J, Martínez-Toldos, P, Udaondo, C, Fernández-Martínez, L, Gutiérrez-Arias, A, Hervás, R, Rodrigo
Rok vydání:	2016
Předmět:	Bevacizumab Diabetic Retinopathy Receptors Vascular Endothelial Growth Factor Spain Cost-Benefit Analysis Ranibizumab Recombinant Fusion Proteins Humans Macular Edema
Zdroj:	Archivos de la Sociedad Espanola de Oftalmologia. 92(5)
ISSN:	1989-7286
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::9800b218ba34fce09612ce0c60d4a45c https://pubmed.ncbi.nlm.nih.gov/28215618 Zobrazit plný text záznamu